Xerostomia therapeutics global market 2024 to reach $2.65 billion by 2028 at rate of 5.4%

The Business Research Company’s Xerostomia Therapeutics Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, June 26, 2024 /EINPresswire.com/ — The xerostomia therapeutics market has experienced robust growth in recent years, expanding from $2.04 billion in 2023 to $2.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidences of xerostomia in the geriatric population, research and development of efficient products for xerostomia, growing awareness about xerostomia-related products, increasing of medical conditions, and rising prevalence of chronic diseases.

Strong Future Growth Anticipated
The xerostomia therapeutics market is projected to continue its strong growth, reaching $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to easy availability of cost-effective medications in the market, increased prevalence of oral health conditions, rising awareness among healthcare practitioners, government initiatives, and increased medication use.

Explore comprehensive insights into the global xerostomia therapeutics market with a detailed sample report:

Growth driver of the xerostomia therapeutics market
The increasing adoption of chemotherapy in cancer treatment is expected to propel the growth of xerostomia therapeutics market going forward. Chemotherapy in cancer treatment refers to the use of powerful medications which is to kill or slow the growth of cancer cells. The rising acceptance of chemotherapy in cancer treatment is mainly due to its effectiveness in specifically targeting and eradicating cancerous cells throughout the body. Xerostomia therapeutics include saliva-stimulating medications or mouth rinses that improve saliva production and enhance taste perception, making it easier for patients to eat and maintain adequate nutrition.

Make your report purchase here and explore the whole industry’s data as well:

Major Players and Market Trends
Key players in the xerostomia therapeutics market include Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd.

Major companies operating in the xerostomia therapeutics market are developing saliva substitutes to mimic the natural composition of saliva, providing relief to those suffering from xerostomia. Saliva substitutes effectively alleviate the discomfort of xerostomia by providing moisture, lubrication, pH balance, cleansing, and potentially other beneficial properties to the oral cavity, thereby improving oral health and quality of life.

Xerostomia Therapeutics Market Segments:
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric

Geographical Insights: North America Leading the Market
North America was the largest region in the xerostomia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding healthcare facilities and increasing awareness of the benefits of xerostomia therapeutics.

Xerostomia Therapeutics Market Definition
Xerostomia therapeutics refer to treatments and medications used to manage dry mouth, a condition characterized by reduced saliva production. These therapies aim to alleviate symptoms such as difficulty swallowing and tasting, as well as prevent dental issues.

Xerostomia Therapeutics Global Market Report 2024 from TBRC covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Xerostomia Therapeutics Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on non-pvc iv bags market size, non-pvc iv bags market drivers and trends, non-pvc iv bags market major players, competitors’ revenues, market positioning, and market growth across geographies. The non-pvc iv bags market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

Liver Diseases Therapeutics Global Market Report 2024

Peptide Therapeutics Global Market Report 2024

About The Business Research Company
The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn